<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Infantile hemangiomas: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Infantile hemangiomas: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Infantile hemangiomas: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denise W Metry, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H70399412"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Infantile hemangiomas (IHs) are benign tumors of vascular endothelium [<a href="#rid1">1-3</a>]. They are the most common vascular tumors of childhood. They are characterized by a growth phase and involution phase. Despite their benign and self-limited nature, some IHs can cause complications such as ulceration or life-altering disfigurement. In addition, they may compromise vital organ function or herald a number of underlying developmental anomalies including, but not limited to, the central nervous system, cardiovascular system, or spine. Infants with cutaneous hemangiomas, most often in the setting of multiple hemangiomas or a solitary, segmental hemangioma, occasionally have additional hemangiomas of the liver, brain, respiratory tract, or gastrointestinal tract. Rarely, visceral hemangiomas can be symptomatic and associated with life-threatening complications.</p><p>The management of IHs will be discussed below. The epidemiology, pathogenesis, clinical features, complications, and evaluation are discussed separately. Other vascular tumors of childhood are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5793.html" rel="external">"Infantile hemangiomas: Evaluation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13727.html" rel="external">"Congenital hemangiomas: Rapidly involuting congenital hemangioma (RICH), noninvoluting congenital hemangioma (NICH), and partially involuting congenital hemangioma (PICH)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/86314.html" rel="external">"Tufted angioma, kaposiform hemangioendothelioma (KHE), and Kasabach-Merritt phenomenon (KMP)"</a>.)</p><p></p><p class="headingAnchor" id="H3831693261"><span class="h1">GENERAL APPROACH</span><span class="headingEndMark"> — </span>The approach to treatment of IH should be individualized, based upon the size of the lesion(s), morphology, location, presence or possibility of complications, potential for scarring or disfigurement, the age of the patient, and the rate of growth or involution at the time of evaluation [<a href="#rid4">4,5</a>]. The potential risk(s) of treatment must be carefully weighed against the potential benefits.</p><p>Consultation with and/or referral to a pediatric dermatologist, vascular anomalies team, or other knowledgeable specialist is warranted for children with hemangiomas with actual or potential risk for complications and/or when therapy is being considered [<a href="#rid6">6</a>]. Such infants should be referred as soon as possible during the early hemangioma proliferation phase, ideally by one month of age [<a href="#rid7">7</a>]. (See <a class="local">'Risk stratification and indications for referral/intervention'</a> below.)</p><p>The management of IH involves clinical examination(s) and education of the family. Depending on the clinical situation and the parents' or caregivers' level of concern, the patient may need to be re-evaluated frequently during the proliferative phase and again before school entry. Serial photographs of the hemangioma can help to monitor the clinical course.</p><p>Education of the family should include information about the natural course; potential complications; treatment indications and timing; and risks, benefits, and expectations of available treatment options for IH. The family should be provided with realistic expectations about the duration of involution and the possibility of permanent, residual changes. In some studies, complete involution has been noted at a median age of four years [<a href="#rid8">8,9</a>]. However, this timeline is highly variable and dependent on hemangioma size, morphology, and location. It must also be emphasized that, in many cases, involution does not result in normal-appearing skin. More than one-half of children with untreated hemangiomas experience permanent, residual changes such as scarring, atrophy, redundant skin, discoloration, and telangiectasias [<a href="#rid10">10</a>].</p><p>Finally, the family should be provided with anticipatory guidance regarding ways to respond to comments and queries from family members and strangers and how to teach their children to respond when closer to school age, if necessary. Parents or caregivers are commonly subject to inappropriate comments from strangers, including accusations of child abuse [<a href="#rid11">11</a>]. Often children, who are usually just curious about the hemangioma, are satisfied to know simply that, "It is a birthmark, it doesn't hurt, and it will get better" [<a href="#rid11">11</a>]. Addressing the psychosocial aspects of care and providing families with emotional support and reassurance is essential for the successful management of hemangiomas [<a href="#rid4">4,11-13</a>].</p><p>When treatment is indicated, the choice of treatment modality depends on the above factors, as well as the availability of certain modalities and the experience of the treating clinician.</p><p class="headingAnchor" id="H7"><span class="h1">RISK STRATIFICATION AND INDICATIONS FOR REFERRAL/INTERVENTION</span><span class="headingEndMark"> — </span>Clinicians should classify an IH as high risk if there is evidence of or potential for the following [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening complications (eg, hemangiomas that compromise vital organ function of the airway, liver, or gastrointestinal tract)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Functional impairment (eg, periorbital hemangiomas that compromise vision) or ulceration</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Associated structural anomalies (eg, PHACE [<strong>p</strong>osterior fossa anomalies, <strong>h</strong>emangioma, <strong>a</strong>rterial anomalies, <strong>c</strong>ardiac anomalies, and <strong>e</strong>ye anomalies] syndrome or LUMBAR [<strong>l</strong>ower-body hemangioma and other cutaneous defects; <strong>u</strong>rogenital anomalies, <strong>u</strong>lceration; <strong>m</strong>yelopathy; <strong>b</strong>ony deformities; <strong>a</strong>norectal malformations, <strong>a</strong>rterial anomalies; and <strong>r</strong>enal anomalies] syndrome) (see  <a class="medical medical_review" href="/z/d/html/13735.html" rel="external">"PHACE syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications", section on 'Lumbosacral lesions'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk of permanent disfigurement, especially when a hemangioma is located in a cosmetically sensitive area</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very large (≥5 cm), rapidly growing cutaneous hemangiomas </p><p></p><p>Examples of high-risk lesions that may require early intervention include [<a href="#rid1">1,7,14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Large, plaque-like (segmental) or combined, superficial, and deep hemangiomas, especially in trauma-prone locations, which are prone to ulceration and resultant scarring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any lesion of the face, especially when of significant size or segmental; hemangiomas of the lip crossing the vermillion  (<a class="graphic graphic_picture graphicRef60003" href="/z/d/graphic/60003.html" rel="external">picture 1</a>), nose ("Cyrano nose"), and auricle are particularly prone to disfigurement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large, nodular, superficial hemangiomas, especially those that exhibit a sharp, "cliff-like" border  (<a class="graphic graphic_picture graphicRef61868" href="/z/d/graphic/61868.html" rel="external">picture 2</a>) or pedunculated lesions (hemangiomas extending from a smaller base), have the greatest risk of leaving permanent fibrofatty tissue that may require surgical revision.</p><p></p><p class="headingAnchor" id="H1910188111"><span class="h1">THE INFANTILE HEMANGIOMA REFERRAL SCORE</span><span class="headingEndMark"> — </span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ihscoring.com%2Fwp-content%2Fuploads%2F2020%2F01%2FPFD-PDF_RESULTATS_US.pdf&amp;token=bJ98wEjwYbR6KcGnbD%2BLoQ6tIoINWhPRt0CCO7P%2BvnhvlNuRjte4S%2BTMwa3zBV066dprvA5zW5s%2Fg%2BN2lP%2B2KXQvpKju54aMxOIEfRmaKmceSOnlx5Ul1LDfnmiRvzrf&amp;TOPIC_ID=5792" target="_blank">Infantile Hemangioma Referral Score (IHReS)</a> tool has been developed to help primary care physicians identify problematic hemangiomas that should be referred to expert centers [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H327419762"><span class="h1">GOALS OF TREATMENT</span><span class="headingEndMark"> — </span>The goals of hemangioma treatment include [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prevention or reversal of life-threatening or function-threatening complications</p><p class="bulletIndent1"><span class="glyph">●</span>Prevention or minimization of disfigurement from residual skin changes</p><p class="bulletIndent1"><span class="glyph">●</span>Minimization of psychosocial distress for the patient and family </p><p class="bulletIndent1"><span class="glyph">●</span>Adequate treatment of ulceration to minimize scarring, bleeding, infection, and pain</p><p></p><p>Importantly, topical and systemic medical therapies for hemangiomas are most effective when initiated as early in the hemangioma growth phase as possible, ideally within the first two to three months after birth.</p><p class="headingAnchor" id="H1057901025"><span class="h1">LOW-RISK AND UNCOMPLICATED HEMANGIOMAS</span></p><p class="headingAnchor" id="H1976405777"><span class="h2">Active nonintervention</span><span class="headingEndMark"> — </span>Active nonintervention (serial observation) is a reasonable approach for many uncomplicated hemangiomas, especially in noncosmetically sensitive locations, because all true IHs involute spontaneously over time. However, the decision not to pursue medical and surgical therapy is not necessarily a passive intervention, since the growth and involution of the hemangioma may need to be monitored and the psychosocial implications, particularly of facial hemangiomas, may need to be anticipated and addressed [<a href="#rid11">11</a>]. Serial photographs of the lesion may be helpful to monitor the involution process and outcome.</p><p class="headingAnchor" id="H2866699471"><span class="h2">Local therapies</span><span class="headingEndMark"> — </span>Local pharmacotherapy is primarily used in the treatment of small and superficial IHs and is not indicated for the treatment of larger, complicated lesions. Data on the efficacy of topical therapies, including topical beta blockers and corticosteroids, are limited.</p><p class="headingAnchor" id="H1379357736"><span class="h3">Topical beta blockers</span></p><p class="headingAnchor" id="H3001607321"><span class="h4">Overview of indications</span><span class="headingEndMark"> — </span>Topical beta blockers (topical <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, topical <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a>, topical <a class="drug drug_general" data-topicid="9042" href="/z/d/drug information/9042.html" rel="external">carteolol</a>) may be used for the treatment of thin (&lt;2 mm in thickness), superficial hemangiomas (eg, hemangiomas of minor cosmetic concern located on the face) as an alternative to observation, particularly if parents or caregivers desire treatment. Topical beta blockers may also have a role in the treatment of ulceration (when minor) and in minimizing rebound growth in children who are being tapered off oral propranolol [<a href="#rid16">16-18</a>]. (See <a class="local">'Rebound growth'</a> below and <a class="local">'Ulcerated hemangiomas'</a> below.)</p><p>If a decision is made to use topical beta blockers, we use topical (ophthalmic) <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> maleate gel forming solution 0.5%. A thin layer (typically one to two drops dependent on surface area) is applied to the hemangioma surface two to three times per day until the patient is 12 months of age or stable improvement is achieved.</p><p class="headingAnchor" id="H1372495701"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Limited evidence suggests that topical beta blockers may have some efficacy in the treatment of superficial hemangiomas. A meta-analysis of observational studies and two large, cohort studies suggested that topical <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> 1% (not available in the United States), topical <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> 0.5%, and topical <a class="drug drug_general" data-topicid="9042" href="/z/d/drug information/9042.html" rel="external">carteolol</a> were effective for the treatment of superficial IH, with response rates of approximately 70 to 80 percent [<a href="#rid19">19-21</a>]. However, in a randomized trial, timolol maleate was not more effective than placebo for the treatment of IH in the early proliferative phase [<a href="#rid22">22</a>]. In this study, 69 infants (mean age 48 days) with focal or segmental hemangiomas received either two drops of timolol maleate solution 0.5% administered topically every 12 hours for 24 weeks or two drops of a saline-based placebo [<a href="#rid22">22</a>]. At 24 weeks, 11 patients (42 percent) treated with timolol achieved the primary outcome of complete or nearly complete resolution of hemangiomas compared with 11 patients (36 percent) in the placebo group, but this difference was not statistically significant. In the intention-to-treat analysis, the odds ratio of complete or almost complete response versus no response was 1.36 (95% CI 0.41-3.13). Treatment was generally well tolerated. Three patients in the timolol group had hypotension one hour post-treatment and one patient had bradycardia, but all were asymptomatic during episodes.</p><p class="headingAnchor" id="H278837653"><span class="h4">Safety</span><span class="headingEndMark"> — </span>Topical <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> is generally well tolerated. In a large, multicenter, retrospective study that included 731 children with hemangiomas predominantly superficial and located in the head/neck area treated with topical timolol 0.5% one drop twice daily for an average of 9.5 months, adverse effects occurred in 25 patients (3.4 percent) and included local irritation (n = 12), ulceration (n = 4), and bronchospasm (n = 3) [<a href="#rid20">20</a>]. None of the children experienced cardiovascular adverse effects or required drug discontinuation.</p><p class="headingAnchor" id="H1447893111"><span class="h3">Topical and intralesional corticosteroids</span><span class="headingEndMark"> — </span>High-potency topical corticosteroids (eg, <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> propionate ointment) have been used in the past for thin, superficial hemangiomas and/or minor ulceration [<a href="#rid23">23</a>]. They are now infrequently used since the introduction of topical <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a>. In the author's experience, topical corticosteroids may be helpful for the treatment of minor and/or recurrent ulceration. Adverse effects of long-term use of topical corticosteroids include skin atrophy, hypopigmentation, and hypertrichosis.</p><p>The use of intralesional corticosteroids, such as <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide 10 to 40 mg/mL, is limited to well-localized hemangiomas [<a href="#rid24">24</a>]. Individual doses should not exceed 3 mg/kg [<a href="#rid25">25</a>]. For eyelid hemangiomas, intralesional corticosteroids should only be administered by an ophthalmologist or other experienced specialist.</p><p>A response is usually noted within two weeks, with continued response over the ensuing six to eight weeks [<a href="#rid26">26</a>]. Serial injections administered at four- to eight-week intervals are sometimes needed. Rebound growth has been reported following injections [<a href="#rid25">25</a>].</p><p>Adverse effects of intralesional corticosteroids most commonly include local skin atrophy from inadvertent leaks to normal surrounding skin. Adrenal suppression from systemic absorption is also a possibility, even with localized use [<a href="#rid27">27-29</a>].</p><p class="headingAnchor" id="H3578300832"><span class="h1">HIGH-RISK AND COMPLICATED HEMANGIOMAS</span><span class="headingEndMark"> — </span>High-risk/complicated hemangiomas include large hemangiomas at increased risk of scarring or disfigurement (eg, large, segmental, and/or facial hemangiomas), life-threatening hemangiomas (eg, airway hemangiomas), hemangiomas carrying functional risks (eg, periocular hemangiomas), and hemangioma ulceration that does not respond to standard wound care (see <a class="local">'Risk stratification and indications for referral/intervention'</a> above). In such cases, systemic therapy is typically required.</p><p class="headingAnchor" id="H3916334285"><span class="h2">When to start treatment</span><span class="headingEndMark"> — </span>We agree with the recommendation of the American Academy of Pediatrics' Clinical Practice Guideline for the Management of Infantile Hemangiomas that infants with high-risk hemangiomas should start treatment or be referred to a specialist at an early age, ideally by four weeks of age [<a href="#rid7">7</a>]. The rationale for early intervention (eg, before the completion of the hemangioma's rapid growth phase) is based on the observation that the most rapid growth of superficial hemangiomas typically occurs between 5.5 and 7.5 weeks of age and that hemangioma precursors are present at birth in nearly two-thirds of the patients [<a href="#rid30">30</a>].</p><p>Treatment started as soon as feasible and before the completion of the proliferative phase, which in most cases occurs by five months of age, may help prevent poor outcomes. Although oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> may show some benefit for hemangiomas that have passed the proliferative phase, the effects are generally significantly smaller. (See  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications"</a> and  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications", section on 'Natural history'</a>.)</p><p class="headingAnchor" id="H4063652695"><span class="h2">First-line therapy</span></p><p class="headingAnchor" id="H2281526900"><span class="h3">Propranolol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a>, a nonselective beta blocker, is the first-line agent for hemangiomas with the potential to impair function or cause permanent disfigurement, if there are no cardiac, neurovascular, or other contraindications  (<a class="graphic graphic_algorithm graphicRef109423" href="/z/d/graphic/109423.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,31</a>]. In 2014, propranolol hydrochloride oral solution was approved by the US Food and Drug Administration for the treatment of proliferating IH requiring systemic therapy [<a href="#rid32">32</a>].</p><p><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> inhibits the growth and induces the regression of IHs [<a href="#rid33">33</a>]. Potential mechanisms of action for propranolol may include vasoconstriction, decreased expression of vascular endothelial growth factor and basic fibroblast growth factor, and/or triggering of apoptosis [<a href="#rid34">34,35</a>].</p><p class="headingAnchor" id="H3719769097"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>In 2008, the serendipitous observation that the use of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> to treat heart failure in two young children with IHs was associated with a change in color, softening, and decrease in size of the hemangiomas led to the initiation of larger observational studies and randomized trials. All studies demonstrated improvement with propranolol [<a href="#rid33">33,36-42</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a large, randomized trial, 456 infants aged five weeks to five months with a proliferating hemangioma of at least 1.5 cm received placebo or <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> (1 mg/kg per day or 3 mg/kg per day) for three or six months [<a href="#rid42">42</a>]. Children with high-risk hemangiomas were not included for ethical reasons. The primary outcome was complete or nearly complete resolution of the hemangioma at week 24, assessed by centralized, blinded evaluation of digital photographs. Complete or nearly complete resolution of the target hemangioma was observed in 60 percent of patients treated with propranolol 3 mg/kg per day for six months versus 4 percent of patients treated with placebo. Ten percent of patients in whom treatment was successful required systemic retreatment during follow-up. Treatment initiation before 10 weeks of age was associated with a higher rate of treatment success (86 percent) [<a href="#rid43">43</a>]. Mild adverse effects, including diarrhea, sleep disorders, bronchial hyperreactivity, cold extremities, upper respiratory tract infection, and fever, occurred in over 90 percent of patients receiving propranolol and in 76 percent of patients receiving placebo. Serious adverse events suspected to be related to propranolol were rare (occurred in single patients only) and included second-degree atrioventricular block, bronchiolitis, hemangioma worsening/ulceration, and bradycardia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2016 network meta-analysis of 18 randomized trials and cohort studies including 1265 children aged two weeks to nine years evaluated the relative expected rates of clearance associated with beta blockers and corticosteroids [<a href="#rid44">44</a>]. Oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> in doses ranging from 1 to 4 mg/kg per day had the largest mean estimate of expected clearance (95 percent, 95% Bayesian credible interval [BCI] 88-99) relative to oral corticosteroids (43 percent, 95% BCI 21-66) and placebo or observation (6 percent, 95% BCI 1-11).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2018 systematic review concluded that, compared with placebo, oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> is effective in inducing complete or almost complete hemangioma clearance without a significant increase in the risk of adverse events [<a href="#rid45">45</a>].</p><p></p><p>Oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> has also been used to treat IHs beyond the proliferative phase [<a href="#rid46">46,47</a>]. In a multicentric, retrospective study, 42 children aged 7 months to 10 years with documented cessation of hemangioma growth were treated with propranolol 1.5 to 3 mg/kg per day for one to eight months [<a href="#rid46">46</a>]. In all children, the rate of involution increased with propranolol compared with the rate of involution during active nonintervention before treatment.</p><p class="headingAnchor" id="H1378810743"><span class="h4">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Treatment with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> should be undertaken in consultation with a pediatric dermatologist or other specialist with expertise in the diagnosis and treatment of pediatric vascular tumors and in the use of propranolol in children  (<a class="graphic graphic_algorithm graphicRef109423" href="/z/d/graphic/109423.html" rel="external">algorithm 1</a>). The pretreatment evaluation (typically outpatient) should include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>History</strong> – History, with focus on cardiovascular and respiratory abnormalities (eg, poor feeding, dyspnea, tachypnea, diaphoresis, wheezing, heart murmur) and family history of heart block or arrhythmia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – Physical examination including cardiac and pulmonary assessment and measurement of heart rate and blood pressure. It should be noted that heart rate is generally more reliable than blood pressure, since obtaining accurate blood pressure readings in infants can be challenging. (See  <a class="medical medical_review" href="/z/d/html/2865.html" rel="external">"The pediatric physical examination: General principles and standard measurements", section on 'Vital signs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrocardiogram </strong>– Electrocardiogram is indicated in children with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heart rate lower than normal for age  (<a class="graphic graphic_table graphicRef77057" href="/z/d/graphic/77057.html" rel="external">table 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>History of arrhythmia or arrhythmia detected during examination</p><p class="bulletIndent2"><span class="glyph">•</span>Family history of congenital heart disease or maternal history of connective tissue disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging studies</strong> – In children with large, segmental head or neck hemangiomas who are at risk of having PHACE (<strong>p</strong>osterior fossa anomalies, <strong>h</strong>emangioma, <strong>a</strong>rterial anomalies, <strong>c</strong>ardiac anomalies, and <strong>e</strong>ye anomalies) syndrome, imaging studies, including cardiac ultrasound or cardiac magnetic resonance imaging (MRI), should be obtained to rule out severe, cardiovascular anomalies that would be a contraindication to <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> use. In these patients, baseline head/neck MRI with angiography is also preferred prior to propranolol initiation. </p><p></p><p class="bulletIndent1">While there is no evidence that <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> increases risk of stroke in infants with PHACE syndrome and cerebrovascular anomalies, consultation with an experienced neurologist or neurovascular specialist is advised in patients with PHACE syndrome categorized as high risk for stroke based on neuroimaging findings [<a href="#rid48">48</a>]. In some higher-risk cases, it has been suggested that propranolol may still be considered, albeit modified with lower initial dosing and slower upward titration. (See  <a class="medical medical_review" href="/z/d/html/13735.html" rel="external">"PHACE syndrome", section on 'Propranolol'</a>.)</p><p></p><p class="headingAnchor" id="H2185248159"><span class="h4">Contraindications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> treatment is contraindicated in infants and children with:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiogenic shock</p><p class="bulletIndent1"><span class="glyph">●</span>Documented chronic and significant sinus bradycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Documented chronic and significant hypotension</p><p class="bulletIndent1"><span class="glyph">●</span>Greater than first-degree heart block</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>History of bronchospasm or wheezing</p><p class="bulletIndent1"><span class="glyph">●</span>Hypersensitivity to <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a></p><p class="bulletIndent1"><span class="glyph">●</span>Preterm infants with corrected age &lt;5 weeks (postnatal age in weeks minus number of weeks preterm)</p><p></p><p class="headingAnchor" id="H1527754996"><span class="h4">Initiation of treatment and dosing</span><span class="headingEndMark"> — </span>In most cases, even in otherwise healthy babies as young as four weeks of age and in preterm infants four weeks of corrected gestational age, treatment can be initiated and managed in an outpatient clinical setting by a clinician with experience in the diagnosis and management of IHs  (<a class="graphic graphic_algorithm graphicRef109423" href="/z/d/graphic/109423.html" rel="external">algorithm 1</a>) [<a href="#rid49">49,50</a>].</p><p>However, in accord with an expert consensus panel, we suggest that hospitalization for the initiation of oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> be considered in the following circumstances [<a href="#rid31">31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infants &lt;4 weeks of age</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants of any age with inadequate social support</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants of any age with comorbid conditions affecting the cardiovascular or respiratory system, including symptomatic airway hemangiomas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infants of any age with conditions affecting blood glucose maintenance</p><p></p><p>We generally start treatment with oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> at 1 mg/kg per day in two divided doses, increasing to 2 mg/kg per day given in two divided doses after one week, and then up to 3 mg/kg per day divided twice daily, dependent on hemangioma severity and response. To reduce the risk of hypoglycemia, propranolol is administered <strong>immediately after feeding</strong>. Administering propranolol after feeds is safer than before feeds, in case the feed is inadequate, and is therefore recommended.</p><p>In case of intercurrent illness associated with poor feeding, treatment should be temporarily held and then resumed at the last prescribed dose. If children present with severe respiratory symptoms, including wheezing, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> should also be temporarily held and then resumed at a lower dose and titrated up more gradually with close monitoring. (See <a class="local">'Adverse effects'</a> below.)</p><p class="headingAnchor" id="H6243753"><span class="h4">Monitoring</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In clinic</strong> – Since the effect of oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> peaks at one to three hours after administration, an expert consensus panel has recommended that patients be monitored with measurement of heart rate and blood pressure at one and two hours after the initial dose and after every dose increase of 0.5 mg/kg/day [<a href="#rid31">31</a>]. This is in accord with the US Food and Drug Administration and European Medicines Agency recommendations. (See  <a class="medical medical_review" href="/z/d/html/2865.html" rel="external">"The pediatric physical examination: General principles and standard measurements", section on 'Heart rate'</a> and  <a class="medical medical_review" href="/z/d/html/16151.html" rel="external">"Evaluation and diagnosis of hypertension in infants between one month and one year of age", section on 'Blood pressure measurement'</a>.)</p><p></p><p class="bulletIndent1">However, in clinical practice, many experts (including the author) and other guidelines do not monitor heart rate and blood pressure in clinic after the first dose and after dose increases  (<a class="graphic graphic_algorithm graphicRef109423" href="/z/d/graphic/109423.html" rel="external">algorithm 1</a>) [<a href="#rid51">51-54</a>]. </p><p></p><p class="bulletIndent1">This approach is supported by data from a large, retrospective study of 783 children who initiated <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> treatment at a median age of 112 days and had heart rate and blood pressure obtained before treatment, at one and two hours after first dose, and, if available, after dose escalation [<a href="#rid55">55</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No symptomatic bradycardia or hypotension requiring immediate intervention or drug discontinuation occurred during monitoring.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mean heart rate change from baseline to one hour was -8.19/min and from baseline to two hours was -9.24/min, but none of the children had a heart rate below the normal range for age.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At initiation and escalation, a decrease in systolic blood pressure below the normal values was noted in 16 of 3141 measurements (0.51 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Between initiation and escalation visits, a decrease in diastolic blood pressure below normal values was noted in 118 of 2382 measurements (4.95 percent).</p><p></p><p class="bulletIndent1">Later in the course of therapy, three infants experienced a serious adverse event: two episodes of symptomatic hypoglycemia and one respiratory event (pneumonia) [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>At home</strong> – Parents or caregivers should be educated about recognizing the signs of serious adverse effects, which include hypotension, bradycardia, wheezing, and hypoglycemia [<a href="#rid56">56</a>]. Early clinical signs of hypoglycemia include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sweating</p><p class="bulletIndent2"><span class="glyph">•</span>Jitteriness</p><p class="bulletIndent2"><span class="glyph">•</span>Irritability</p><p class="bulletIndent2"><span class="glyph">•</span>Cyanosis</p><p class="bulletIndent2"><span class="glyph">•</span>Poor feeding</p><p class="bulletIndent2"><span class="glyph">•</span>Hypothermia</p><p class="bulletIndent2"><span class="glyph">•</span>Lethargy</p><p></p><p class="bulletIndent1">Importantly, all these clinical signs may be masked by beta blockers <strong>except</strong> for sweating. Thus, sweating may be the most reliable, early sign of hypoglycemia to watch for. </p><p></p><p class="bulletIndent1">Routine screening of serum glucose is not indicated because the timing of hypoglycemic events is variable, unpredictable, and almost invariably associated with continued intake of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> during a fasting state. In addition, asymptomatic hypoglycemia was not detected in studies that included a random serum glucose as part of routine monitoring [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children", section on 'Clinical features'</a>.)</p><p></p><p class="headingAnchor" id="H3035453362"><span class="h4">Assessment of response and treatment duration</span><span class="headingEndMark"> — </span>Children with IHs treated with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> should be followed at regular intervals for response assessment and dose adjustment for weight gain. Although a significant response (reduction in size) is often seen after three to four months of propranolol treatment, many experts continue therapy beyond the proliferative phase. Thus, treatment is generally continued until 6 to 18 months of age but varies depending on the hemangioma size, location, complications, and response and when (at what age) treatment was initiated.</p><p>An open-label, phase 3, multicenter study evaluated the rate of hemangioma resolution in children with high-risk hemangiomas treated with oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> up to the age of 12 months [<a href="#rid57">57</a>]. In this study, 43 children aged 35 to 150 days with hemangiomas that were life threatening (with periorbital, nasal, labial, laryngotracheal, or limb joint location), disfiguring, or ulcerated and nonresponsive to wound care received oral propranolol 3 mg/kg per day in two divided doses for at least six months or up to the age of 12 months if complete success (defined as hemangioma disappearance or persistence of only a minimal degree of telangiectasias, erythema, skin thickening, soft tissue swelling, and absence of functional impact) was not achieved. Complete success was achieved by 34 patients (76 percent, 95% CI 61.7-86.3 percent) treated for a minimum of six months and up to a maximum of 12 months of age. After the first six months of treatment, success was achieved by only 21 patients (47 percent, 95% CI 32.7-61.1 percent).</p><p>A lack of response to treatment with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> is rare. In a French, retrospective, multicenter study including 1130 children treated with propranolol, 10 children (0.9 percent) had propranolol-resistant hemangiomas [<a href="#rid58">58</a>]. Resistance was defined as continued growth during the proliferative phase or no involution during the postproliferative phase after &gt;4 weeks of oral propranolol at greater than 2 mg/kg per day. Five of the 10 children who did not respond to propranolol had hemangiomas in the postproliferative phase and were older than eight months at the start of treatment. Three children with hemangiomas in the proliferative phase showed a rapid response to adjuvant systemic corticosteroids.</p><p class="headingAnchor" id="H3341953426"><span class="h4">Rebound growth</span><span class="headingEndMark"> — </span>Rebound growth after <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> discontinuation has been noted in approximately 14 to 25 percent of children [<a href="#rid59">59-61</a>]. The factors associated with the risk of relapse are not completely understood. Of note, rebound growth has been noted in one patient after administration of the beta-adrenergic receptor agonist salbutamol 10 months after stopping propranolol treatment [<a href="#rid62">62</a>].</p><p>Some children with rebound growth may need a second course of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>. Topical beta blockers may be used to treat mild relapses. However, mild relapses do not require treatment in most cases, and parents or caregivers can be reassured about the eventual involution of the lesion.</p><p>In a single-institution study including 158 children with hemangiomas located predominantly in the head and neck region who were treated with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> for 3 to 12 months, relapse occurred in 40 children (25 percent) 0.5 to 5 months after treatment cessation [<a href="#rid61">61</a>]. In one-half, the relapse was mild and did not require retreatment. Factors associated with an increased risk of relapse included segmental distribution and increased depth of the hemangioma.</p><p class="headingAnchor" id="H1138069082"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span>Children treated with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> should be closely monitored for adverse effects. In a review of 906 French children (median age 114 days) treated with propranolol for complicated hemangiomas, one or more adverse reactions occurred in 81 children (9 percent) [<a href="#rid63">63</a>]. Serious adverse effects (cardiac, respiratory, and hypoglycemia) occurred in 24 patients (2.6 percent).</p><p>Serious adverse effects of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> therapy for hemangiomas, which include hypoglycemia, hypotension, bradycardia, bronchospasm, and hyperkalemia, are infrequent [<a href="#rid42">42,64,65</a>]. Restless sleep, constipation or diarrhea, and cold extremities or acrocyanosis are more commonly reported [<a href="#rid65">65</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypoglycemia</strong> – Of the potential serious adverse effects, hypoglycemia is the most worrisome. To reduce this risk, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> should be administered during the daytime hours <strong>shortly after a feeding</strong>. Propranolol should be discontinued during periods of illness with poor oral intake [<a href="#rid31">31,56,66</a>]. Patients noted to be at increased risk for propranolol-induced hypoglycemia include children who were previously treated with prolonged courses of systemic glucocorticoids and patients with high-output cardiac failure secondary to a large liver hemangioma [<a href="#rid66">66,67</a>]. Symptomatic hypoglycemia during propranolol use has also been reported in older children and, thus, is not age dependent [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular/respiratory</strong> – A study using data from the French national medical administrative database, covering nearly 100 percent of the French population, confirmed an overall good safety profile of oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> for children &lt;3 years without underlying cardiovascular disease ("healthy") [<a href="#rid68">68</a>]. Among 1484 healthy children who received at least two deliveries of oral propranolol, only two children (0.13 percent) had a cardiovascular adverse effect compared with 11 of 133 children (8.3 percent) with an underlying congenital cardiovascular disease (standardized morbidity ratio [SMR] 2.8, 95% CI 0-6.7, and SMR 6.0, 95% CI 2.5-9.6, respectively). A moderately increased risk of respiratory adverse events was observed among healthy children exposed to propranolol (SMR for bronchiolitis 1.6, 95% CI 1.1-2.1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sleep behavior/neurologic</strong> – There have been concerns regarding the effects of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> on the central nervous system, such as sleep disturbance and agitation. However, studies examining sleep behavior in infants treated with propranolol found a modest or no increase in sleep disturbance compared with infants not taking propranolol [<a href="#rid69">69,70</a>]. Moreover, a study assessing the cognitive and memory functions at age 5 to 7.5 years in children treated with propranolol during infancy did not find any difference in performance on standardized tests compared with the general population in the same age range [<a href="#rid71">71</a>].</p><p></p><p class="headingAnchor" id="H3908011201"><span class="h3">Telemedicine recommendations for initiation of oral propranolol</span><span class="headingEndMark"> — </span>The Hemangioma Investigator Group has published recommendations regarding the appropriate use of telemedicine for the initial evaluation, treatment initiation, dosing, and follow-up evaluation for patients with IHs requiring treatment with oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> [<a href="#rid72">72</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates for telemedicine initiation</strong> − The Hemangioma Investigator Group suggests that telemedicine initiation of oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> may be considered for infants at <strong>standard risk</strong> who meet the following criteria [<a href="#rid72">72</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adjusted gestational age &gt;5 weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal birth weight.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal cardiovascular examination within the previous four weeks (including &gt;1 documented heart rate after nursery discharge).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal respiratory examination within the previous four weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Healthy in the 24 to 48 hours prior to scheduled telemedicine visit (especially no respiratory and gastrointestinal signs and symptoms).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IH pattern and distribution <strong>do not</strong><em> </em>confer risk of PHACE syndrome or LUMBAR (<strong>l</strong>ower-body hemangioma and other cutaneous defects; <strong>u</strong>rogenital anomalies, <strong>u</strong>lceration; <strong>m</strong>yelopathy; <strong>b</strong>ony deformities; <strong>a</strong>norectal malformations, <strong>a</strong>rterial anomalies; and <strong>r</strong>enal anomalies) syndrome.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lack of ulceration or minimal/superficial ulceration.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Caregiver is able to understand instructions and demonstrate comprehension (eg, by repeating instructions provided during visit).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple IHs with normal liver ultrasound and without cutaneous IH conferring higher risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In-person evaluation</strong> – The Hemangioma Investigator Group recommends in-person evaluation for <strong>infants at high risk</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Corrected gestational age &lt;5 weeks</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Abnormal cardiovascular examinations or investigations <strong>or</strong> those who lack documentation of this in the postnatal period</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medium to high risk of PHACE syndrome (ie, large, segmental, facial or scalp IH in segments S1, S3, S4)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Medium to high risk of LUMBAR syndrome (ie, segmental, perineal, and/or lumbosacral body IH with or without visible, associated, anatomic abnormalities)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Significant IH ulceration</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ongoing poor oral feeding or poor weight gain</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>IH with symptoms of airway compromise (eg, stridor) or beard area IH at high risk for airway IH</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known pulmonary disease, including ongoing respiratory compromise (eg, dyspnea, frequent wheezing or history of bronchospasm)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent or ongoing hypoglycemia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known or suspected congenital heart disease or suggestive symptoms</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extensive hepatic hemangiomas</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known brain malformations</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of congenital heart disease or sudden death in first-degree relative</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal history of connective tissue disorder</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation via telemedicine and dosing</strong> – For patients who are candidates for telemedicine initiation, the Hemangioma Investigator Group suggests a starting dose of 0.5 mg/kg per day divided twice daily and increasing every three to four days by 0.5 mg/kg per day to the target dose of 2 to 3 mg/kg per day divided twice daily. </p><p></p><p class="headingAnchor" id="H2552489834"><span class="h3">Sequential/concurrent use of propranolol and topical timolol</span><span class="headingEndMark"> — </span>Sequential or concurrent use of oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and topical <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> may allow for a shorter duration of oral propranolol therapy, thus reducing the risk of potential adverse effects, facilitating the tapering of oral propranolol, and preventing rebound growth [<a href="#rid18">18,73</a>]. (See <a class="local">'Topical beta blockers'</a> above.)</p><p>In a retrospective study of 559 children treated at a single institution with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> only, <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> only, propranolol to timolol, timolol to propranolol to timolol, and timolol to propranolol, those who received propranolol followed by timolol had a median treatment course 2.2 months shorter than those receiving propranolol alone [<a href="#rid18">18</a>]. None of the children in the propranolol to timolol group needed to restart propranolol compared with 13 percent of those treated with propranolol alone.</p><p class="headingAnchor" id="H3897840482"><span class="h3">Other oral beta blockers</span><span class="headingEndMark"> — </span>A few trials suggest that <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a><strong> (a selective beta-1 blocker) and </strong><a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">nadolol</a><strong> (a nonselective beta blocker) </strong>may be as effective as <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> for the treatment of proliferative hemangiomas, potentially with a lower rate of adverse effects such as bronchoreactivity and sleep disturbances [<a href="#rid74">74-78</a>]. However, their use is limited by the lack of a widely available oral formulation suitable for infants:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>In a large, randomized, open-label trial, 377 infants</strong> (mean age 10 weeks) with problematic hemangiomas were treated with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> 2 mg/kg per day in three divided doses or <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a> 1 mg/kg per day in a single dose for at least six months and then followed up for two years [<a href="#rid79">79</a>]. At six months in the intention-to-treat population, the primary outcome of "any response" was achieved in 93.7 percent of infants in the propranolol group and in 92.5 percent of infants in the atenolol group (difference 1.2 percent, 95% CI -4.1 to 6.6 percent). At 96 weeks, a complete or nearly complete response was noted in 82.1 percent of infants in the propranolol group and in 79.7 percent of infants in the atenolol group (difference 2.4 percent, 95% CI -5.5 to 10.4 percent). Adverse events occurred more frequently in the propranolol group than in the atenolol group (70 versus 44 percent) and included diarrhea, sleep disturbance, cool extremities, and bradycardia. Severe adverse events occurred with similar frequency in the two groups (2.6 percent in the propranolol group and 1.6 percent in the atenolol group).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial compared <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and <a class="drug drug_general" data-topicid="9672" href="/z/d/drug information/9672.html" rel="external">nadolol</a> in escalating doses up to 2 mg/kg/day in 71 infants aged one to six months with problematic IHs [<a href="#rid78">78</a>]. At 24 weeks, the mean size of involution compared with baseline was 97.9 percent in the nadolol group versus 89.1 percent in the propranolol group (difference 8.8 percent, 95% CI 2.7-14.9 percent). The mean color fading was 94.5 percent in the nadolol group versus 80.5 percent in the propranolol group (difference 14 percent, 95% CI 7.2-30 percent). Both medications were well tolerated. Adverse events occurred with similar frequency in the nadolol and propranolol groups (77 and 94 percent, respectively) and included predominantly upper respiratory infections, diarrhea, vomiting, and sleep disturbance.</p><p></p><p class="headingAnchor" id="H3355821867"><span class="h2">Second-line therapies</span></p><p class="headingAnchor" id="H7862164"><span class="h3">Systemic corticosteroids</span><span class="headingEndMark"> — </span>Treatment of complicated hemangiomas with systemic corticosteroids has been largely supplanted by treatment with systemic beta blockers. However, systemic corticosteroids remain a treatment option for patients with complicated hemangiomas for whom treatment with beta blockers is contraindicated. (See <a class="local">'Contraindications'</a> above.)</p><p>In select, severe cases, combining beta blockers with a short course of systemic corticosteroids may be considered in order to shorten the response time [<a href="#rid80">80</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – The usual starting dose for <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> is 1 to 3 mg/kg per day. A single morning dose is preferred to minimize adrenal suppression. A response (stabilization with or without regression) is usually seen within the first few weeks [<a href="#rid81">81,82</a>].</p><p></p><p class="bulletIndent1">Treatment is generally continued for several months or more, depending upon the indications for treatment, the response, and the child's age at initiation [<a href="#rid13">13</a>]. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> should be slowly discontinued since abrupt discontinuation or rapid tapering of glucocorticoids while a hemangioma is still in its active growth phase may result in rebound proliferation and to avoid adrenal insufficiency [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy versus </strong><strong>propranolol</strong> – In a few studies, systemic corticosteroids have been shown to have an efficacy similar to that of oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> in inducing volume reduction of IHs [<a href="#rid83">83-85</a>].</p><p></p><p class="bulletIndent1">In a small, noninferiority, randomized trial, 34 children aged 0.3 to 8.2 months with hemangiomas located predominantly on the face were randomly assigned to treatment with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> 2 mg/kg/day in three divided doses or <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> 2 mg/kg/day in a single dose for 16 weeks [<a href="#rid83">83</a>]. A response to treatment, broadly defined as stop of progression and volume decrease, was achieved by 96 and 92 percent of patients in the propranolol and systemic corticosteroid groups, respectively. Adverse effects were generally mild and occurred with equal frequency in both groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of systemic corticosteroids are more likely to develop with higher doses and courses of six months or longer and resolve with drug tapering:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most common complication is the development of a cushingoid facies, which usually begins within the first one to two months of treatment [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Personality changes (eg, depressed mood, agitation, insomnia, restlessness) develop in approximately one-third of infants, usually during the first two weeks of therapy [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Delayed skeletal growth, which may be more readily apparent since a child grows most rapidly during the first year of life, results from a temporary inhibition of collagen synthesis. However, nearly all children catch up to the normal growth curve once therapy has been discontinued, usually by two years of age [<a href="#rid86">86,87</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastric upset occurs in at least 20 percent of infants and can be relieved with histamine 2 (H2) blockers or proton pump inhibitors, which many clinicians initiate routinely along with glucocorticoids [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serious corticosteroid complications, such as aseptic necrosis of the femoral head, hypertension, osteoporosis, and cataracts, are extremely rare in children [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Supraphysiologic doses of glucocorticoids may suppress the hypothalamic-pituitary-adrenal axis. "Stress doses" of glucocorticoids may be necessary for infants who require medical or surgical hospitalization while undergoing glucocorticoid therapy for IH [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1">Systemic corticosteroids have immunosuppressive effects and can increase the risk for infections [<a href="#rid89">89-91</a>]. We do not routinely administer <em>Pneumocystis </em>pneumonia (PCP) prophylaxis to children being treated with systemic glucocorticoids for IH. However, PCP prophylaxis may be warranted in infants who have other risk factors for PCP (eg, premature infants with significant, concomitant medical problems). (See  <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">"Glucocorticoid effects on the immune system"</a> and  <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"</a>.)</p><p></p><p class="bulletIndent1">Live-virus vaccines (eg, measles, mumps, rubella [MMR]; varicella; rotavirus) should not be administered while infants are taking supraphysiologic glucocorticoid doses. In addition, because the <a class="drug drug_general" data-topicid="10038" href="/z/d/drug information/10038.html" rel="external">varicella vaccine</a> is not administered until children are at least one year of age, infants receiving glucocorticoid therapy should avoid exposure to individuals with varicella infection. (See  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Infants and children'</a>.)</p><p></p><p class="bulletIndent1">Immunization for diphtheria and tetanus may not be effective in some patients when administered during systemic glucocorticoid therapy [<a href="#rid89">89</a>]. Diphtheria and tetanus titers can be used to confirm protection.</p><p></p><p class="headingAnchor" id="H2416110038"><span class="h3">Surgical therapies</span><span class="headingEndMark"> — </span>When a hemangioma poses primarily cosmetic concerns, therapeutic intervention must be tailored on an individual basis. In addition to systemic, topical, and intralesional medications, therapeutic options include laser therapy and surgery.</p><p class="headingAnchor" id="H2705969490"><span class="h4">Pulsed dye laser</span><span class="headingEndMark"> — </span>The pulsed dye laser cannot be expected to affect thicker, superficial hemangiomas or those with deep involvement, since the depth of laser penetration is only 1.2 mm. The most accepted use of pulsed dye laser in the management of hemangiomas is the treatment of ulceration and postinvolution erythema and telangiectasias [<a href="#rid5">5</a>]. Small, thin, superficial hemangiomas early in the proliferative phase may also be appropriate candidates for pulsed dye laser [<a href="#rid92">92</a>]. The indications, efficacy, and adverse effects of pulsed dye laser therapy for IHs are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13638.html" rel="external">"Laser and light therapy for cutaneous vascular lesions", section on 'Infantile hemangiomas'</a>.)</p><p class="headingAnchor" id="H1712372227"><span class="h4">Excisional surgery</span><span class="headingEndMark"> — </span>Surgical excision is generally reserved for involuted lesions with residual scars or loose skin; hemangiomas in cosmetically sensitive areas with inadequate involution by school age; and pedunculated, cutaneous hemangiomas (because of the likelihood of residual loose skin) [<a href="#rid8">8,81,93</a>]. Excisional surgery may also be considered for severely ulcerated hemangiomas that prove refractory to medical therapy. In cases without complication, but for which there is uncertainty about the outcome, the benefits and risks of surgical intervention must be carefully considered since the results of spontaneous involution are often better than a surgical scar [<a href="#rid82">82,94</a>].</p><p class="headingAnchor" id="H2522118101"><span class="h4">Embolization</span><span class="headingEndMark"> — </span>Rarely, large, visceral (especially hepatic) hemangiomas or those complicated by severe bleeding have been treated with arterial embolization after failure of medical therapy [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H2050566008"><span class="h1">SPECIAL SITUATIONS</span></p><p class="headingAnchor" id="H190200001"><span class="h2">Periocular hemangiomas</span><span class="headingEndMark"> — </span>Periocular hemangiomas (and especially those that are larger than 1 cm, involve the upper medial eyelid, and have a deep component) can compromise vision and cause amblyopia, astigmatism, or strabismus [<a href="#rid95">95</a>]. These hemangiomas should be evaluated and monitored by an ophthalmologist experienced with hemangiomas and their treatment [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Superficial, periocular hemangiomas have been successfully treated with topical beta blockers [<a href="#rid96">96,97</a>]. Surgical excision may also be an option for small, localized lesions [<a href="#rid98">98-101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vision-threatening cases are generally treated systemically with <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> or, less commonly, with intralesional corticosteroids [<a href="#rid24">24,37,102-105</a>]. Intralesional corticosteroids should be managed by a specialist, most often an ophthalmologist with knowledge and experience in this area. Rare but serious side effects, including eyelid necrosis, central retinal artery occlusion, and adrenal suppression, have been reported [<a href="#rid106">106-110</a>].</p><p></p><p class="headingAnchor" id="H4117078265"><span class="h2">Ulcerated hemangiomas</span></p><p class="headingAnchor" id="H124044330"><span class="h3">Wound care and topical agents</span><span class="headingEndMark"> — </span>Gentle and meticulous local wound care is the mainstay of ulcer therapy and is particularly important for lesions in locations subject to trauma and infection, such as the perineum  (<a class="graphic graphic_picture graphicRef74768" href="/z/d/graphic/74768.html" rel="external">picture 3</a>). Local wound care reduces pain and helps to prevent secondary infection [<a href="#rid111">111</a>]. Commonly used therapies include topical antibiotics, barrier creams, and nonstick dressings [<a href="#rid112">112</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wound care</strong> − Very gentle debridement of crusted wounds with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> soaks two to three times daily may also be helpful, since crusting prevents re-epithelization and favors infection  (<a class="graphic graphic_table graphicRef139807" href="/z/d/graphic/139807.html" rel="external">table 2</a>). For ulcerated hemangiomas in the diaper area, gentle cleansing with diaper changes is recommended. When possible, wipes should be avoided and the area cleansed in the bath or by using a spritz bottle with soapy water and gently patted dry, followed by a thick layer of barrier ointment, which can be explained to parents/caregivers as similar to "frosting on a cake."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical therapies</strong> − There are a few reports of successful use of topical <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> for the treatment of ulcerated hemangiomas [<a href="#rid17">17,113-115</a>]. In one retrospective analysis of 30 children with hemangiomas with focal to 3 cm ulcerations predominantly located in intertriginous areas, treatment with one drop twice daily of timolol 0.5% gel led to ulcer resolution in 21 patients after an average of 93 days [<a href="#rid17">17</a>]. (See <a class="local">'Topical beta blockers'</a> above.)</p><p></p><p class="bulletIndent1">Topical <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> gel or <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> ointment, often used in combination with topical <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">mupirocin</a>, have proved to be safe and efficacious for ulceration, particularly in intertriginous or moist areas, such as the perineum [<a href="#rid111">111</a>].</p><p></p><p class="headingAnchor" id="H3450185992"><span class="h3">Oral propranolol</span><span class="headingEndMark"> — </span>We suggest oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> in addition to meticulous wound care and appropriate analgesia for the treatment of ulcerated hemangiomas that may cause permanent disfigurement, interfere with daily life activities (eg, diaper changes, bathing, feeding, sleeping), and/or are unresponsive to wound care and pain and infection control. (See <a class="local">'Propranolol'</a> above.)</p><p>A beneficial effect of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> at standard doses for ulcerated hemangiomas has been reported in several case series [<a href="#rid116">116-120</a>]. However, it has been suggested that lower doses of oral propranolol (ie, less than or equal to 1 mg/kg/day) may be associated with shorter healing times [<a href="#rid121">121</a>].</p><p>In a large, retrospective, cohort study that included 436 patients with ulcerated IH (median age at ulceration was 13.7 weeks), treatment included <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> and wound care, wound care and pulsed dye laser, systemic beta blockers, or multimodal therapy [<a href="#rid121">121</a>]. Among the 87 patients who received <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and had dosing information available, after adjusting for IH size, a dose of propranolol greater than 1 mg/kg/day was associated with a twofold risk of longer healing time compared with a dose less than or equal to 1 mg/kg/day (hazard ratio [HR] 2.04, 95% CI 1.11-3.73).</p><p class="headingAnchor" id="H584645721"><span class="h3">Analgesia</span><span class="headingEndMark"> — </span>The pain associated with ulceration can be severe. Affected infants commonly suffer from sleep disturbance and increased irritability. Use of oral <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> (<strong>without</strong> <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">codeine</a>) or a topical anesthetic agent (ie, <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> hydrochloride 2% to 5% ointment) may be warranted. To avoid the risk of lidocaine toxicity, parents or caregivers should be instructed to apply only a pea-sized amount of lidocaine to the affected area no more than three times per day. (See  <a class="medical medical_review" href="/z/d/html/6254.html" rel="external">"Pain in children: Approach to pain assessment and overview of management principles", section on 'Pharmacologic therapy'</a>.)</p><p>Eutectic mixture of local anesthetics (EMLA) should be avoided in infants less than three months of age because it contains <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">prilocaine</a> hydrochloride, which has been associated with infantile methemoglobinemia. (See  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia", section on 'Topical anesthetics'</a>.)</p><p class="headingAnchor" id="H1473559985"><span class="h3">Pulsed dye laser</span><span class="headingEndMark"> — </span>Pulsed dye laser 595 nm can be used as an adjunctive treatment for ulcerated hemangiomas that fail to heal after medical therapy and optimal wound care [<a href="#rid1">1</a>]. Treatment can be repeated at two- to four-week intervals. (See  <a class="medical medical_review" href="/z/d/html/13638.html" rel="external">"Laser and light therapy for cutaneous vascular lesions", section on 'Infantile hemangiomas'</a>.)</p><p class="headingAnchor" id="H633991690"><span class="h2">Airway hemangiomas</span><span class="headingEndMark"> — </span>Because of the small caliber of the infant airway, a growing airway hemangioma can lead to life-threatening airway obstruction. (See  <a class="medical medical_review" href="/z/d/html/5794.html" rel="external">"Infantile hemangiomas: Epidemiology, pathogenesis, clinical features, and complications", section on 'Airway hemangiomas'</a>.)</p><p>Systemic <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> is generally the first line of therapy for children with symptomatic airway hemangiomas [<a href="#rid36">36,122-124</a>]. Laser ablation, intralesional steroids, and/or surgical debulking are occasional second-line therapies [<a href="#rid125">125</a>]. Rarely, tracheotomy may be required.</p><p>In a multicenter study, 27 infants aged one to five months with airway hemangiomas were treated with oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> 2 mg/kg per day for a median time of 15 months (range 7 to 34 months) [<a href="#rid126">126</a>]. Eleven children were treated with propranolol alone, whereas 16 children received intralesional corticosteroid injection at the time of propranolol initiation. Stridor generally resolved within a day of initiation of propranolol treatment. However, additional therapy, including systemic steroids, laser ablation, or surgical excision, was required in 16 children because of recurrence of respiratory symptoms.</p><p class="headingAnchor" id="H2034144191"><span class="h2">High-output failure</span><span class="headingEndMark"> — </span>Infants with significant hepatic or very large cutaneous hemangiomas may rarely develop high-output heart failure within the first several months of life. Treatment in such cases may include systemic <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> and/or glucocorticoids, hepatic arterial embolization in selected hepatic cases, and/or treatment of heart failure (with fluid restriction, diuretics, and <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> as indicated) [<a href="#rid127">127-130</a>].</p><p class="headingAnchor" id="H295343597"><span class="h2">PHACE syndrome</span><span class="headingEndMark"> — </span>The presence of severe arterial anomalies may restrict or modify the use of <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> in a small subset of patients with PHACE (<strong>p</strong>osterior fossa anomalies, <strong>h</strong>emangioma, <strong>a</strong>rterial anomalies, <strong>c</strong>ardiac anomalies, and <strong>e</strong>ye anomalies) syndrome (MIM #606519) [<a href="#rid131">131</a>]. In addition to large, facial hemangiomas, patients with this disorder may manifest abnormalities of the cerebral, cervical, and cardiac vasculature. (See  <a class="medical medical_review" href="/z/d/html/13735.html" rel="external">"PHACE syndrome"</a>.)</p><p>It is known that a small percentage of patients with PHACE syndrome and severe cerebral or cervical anomalies develop acute arterial ischemic stroke, most often during infancy or toddlerhood [<a href="#rid132">132</a>]. Thus, a theoretical concern has been raised that propranolol-induced hypotension and reduced cerebrovascular perfusion in patients with already compromised cerebral vasculature could increase the risk of stroke in this population, though this has not been demonstrated in clinical practice.</p><p>While <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> may certainly be contraindicated in the setting of significant cardiovascular anomalies, this is usually not the case for the majority of patients with cerebrovascular anomalies, unless those anomalies place the infant in the high-risk category for stroke  (<a class="graphic graphic_table graphicRef110883" href="/z/d/graphic/110883.html" rel="external">table 3</a>) [<a href="#rid131">131</a>]. The risks and benefits of propranolol treatment for patients with PHACE syndrome who have high-risk magnetic resonance angiography (MRA) features should be discussed in consultation with neurology and/or cardiology specialists [<a href="#rid31">31</a>]. If the potential benefits of propranolol treatment are deemed to outweigh the risks, propranolol should be given at the lowest possible dose, with slow upward dose titration and three-times-daily dosing [<a href="#rid31">31</a>]. This schedule is aimed at minimizing abrupt changes in systolic blood pressure, which is a known risk factor for stroke. (See  <a class="medical medical_review" href="/z/d/html/13735.html" rel="external">"PHACE syndrome", section on 'Propranolol'</a>.)</p><p class="headingAnchor" id="H1367641819"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120263.html" rel="external">"Society guideline links: Infantile hemangiomas and PHACE syndrome"</a>.)</p><p class="headingAnchor" id="H376724667"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87107.html" rel="external">"Patient education: Hemangioma (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H47"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> − The approach to the treatment and choice of treatment modality for infantile hemangioma (IH) should be individualized depending upon the size and location of the lesion(s), presence of complications, potential for scarring or disfigurement, rate of growth or involution at the time of evaluation, potential risk(s) and benefits of treatment, availability of the various modalities, and experience of the treating clinician. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ihscoring.com%2Fwp-content%2Fuploads%2F2020%2F01%2FPFD-PDF_RESULTATS_US.pdf&amp;token=bJ98wEjwYbR6KcGnbD%2BLoQ6tIoINWhPRt0CCO7P%2BvnhvlNuRjte4S%2BTMwa3zBV066dprvA5zW5s%2Fg%2BN2lP%2B2KXQvpKju54aMxOIEfRmaKmceSOnlx5Ul1LDfnmiRvzrf&amp;TOPIC_ID=5792" target="_blank">Infantile Hemangioma Referral Score (IHReS)</a> tool has been developed to help primary care physicians identify problematic hemangiomas that should be referred to expert centers. (See <a class="local">'General approach'</a> above and <a class="local">'Risk stratification and indications for referral/intervention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of treatment</strong> − The goals of treatment include the prevention or reversal of life- or function-threatening complications; prevention or minimization of disfigurement, bleeding, infection, and pain; and minimization of psychosocial distress for the patient and family. Medical therapies for hemangiomas are most effective when initiated as early in the hemangioma proliferative phase as possible, ideally within the first two to three months after birth. (See <a class="local">'Goals of treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk/uncomplicated infantile hemangiomas</strong> − We suggest active nonintervention for uncomplicated hemangiomas that are not disfiguring (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Active nonintervention requires regular monitoring of the clinical course and attention to the psychosocial implications for the child and family. (See <a class="local">'Active nonintervention'</a> above.)</p><p></p><p class="bulletIndent1">For thin, superficial, uncomplicated hemangiomas in cosmetically sensitive locations, topical <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> may also be considered. (See <a class="local">'Topical beta blockers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk/complicated infantile hemangiomas</strong> − We recommend oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> as the first-line agent for the treatment of complicated hemangiomas with the potential to impair function or cause disfigurement (eg, periorbital hemangiomas) (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Treatment is generally started with 1 mg/kg per day and then gradually increased to the target dose of 2 to 3 mg/kg per day  (<a class="graphic graphic_algorithm graphicRef109423" href="/z/d/graphic/109423.html" rel="external">algorithm 1</a>). The most significant side effect of oral propranolol is hypoglycemia. This risk can be minimized by educating caregivers to always administer the medication <strong>after</strong> an adequate feed and to hold propranolol when oral intake is poor or absent. (See <a class="local">'Propranolol'</a> above.)</p><p></p><p class="bulletIndent1">Systemic corticosteroids are alternative agents for patients with complicated hemangiomas for whom treatment with beta blockers is contraindicated or may be used as combined therapy in severe, select cases. Surgical excision is generally reserved for involuted lesions with residual scars or loose skin; hemangiomas with inadequate involution in cosmetically sensitive areas; and pedunculated, cutaneous hemangiomas. (See <a class="local">'Second-line therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Periocular infantile hemangiomas</strong> − Children with periorbital IH should be evaluated and monitored by an ophthalmologist who is experienced in the treatment of hemangiomas. (See <a class="local">'Periocular hemangiomas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ulcerated infantile hemangiomas</strong> − We suggest oral <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a> in addition to meticulous wound care and appropriate analgesia for the treatment of ulcerated hemangiomas that may cause permanent disfigurement, interfere with daily life activities, or do not respond to wound care measures (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Ulcerated hemangiomas'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and Management of Infantile Hemangioma. Pediatrics 2015; 136:e1060.</a></li><li><a class="nounderline abstract_t">Darrow DH, Greene AK, Mancini AJ, et al. Diagnosis and Management of Infantile Hemangioma: Executive Summary. Pediatrics 2015; 136:786.</a></li><li><a class="nounderline abstract_t">Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017; 390:85.</a></li><li><a class="nounderline abstract_t">Frieden IJ, Eichenfield LF, Esterly NB, et al. Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 1997; 37:631.</a></li><li><a class="nounderline abstract_t">Frieden IJ. Which hemangiomas to treat--and how? Arch Dermatol 1997; 133:1593.</a></li><li><a class="nounderline abstract_t">Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122:360.</a></li><li><a class="nounderline abstract_t">Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics 2019; 143.</a></li><li><a class="nounderline abstract_t">Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg 2012; 130:619.</a></li><li><a class="nounderline abstract_t">Bauland CG, Lüning TH, Smit JM, et al. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg 2011; 127:1643.</a></li><li><a class="nounderline abstract_t">Baselga E, Roe E, Coulie J, et al. Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy. JAMA Dermatol 2016; 152:1239.</a></li><li><a class="nounderline abstract_t">Tanner JL, Dechert MP, Frieden IJ. Growing up with a facial hemangioma: parent and child coping and adaptation. Pediatrics 1998; 101:446.</a></li><li><a class="nounderline abstract_t">Metry DW, Hebert AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol 2000; 136:905.</a></li><li><a class="nounderline abstract_t">Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999; 341:173.</a></li><li><a class="nounderline abstract_t">Luu M, Frieden IJ. Haemangioma: clinical course, complications and management. Br J Dermatol 2013; 169:20.</a></li><li><a class="nounderline abstract_t">Léauté-Labrèze C, Baselga Torres E, Weibel L, et al. The Infantile Hemangioma Referral Score: A Validated Tool for Physicians. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Blatt J, Morrell DS, Buck S, et al. β-blockers for infantile hemangiomas: a single-institution experience. Clin Pediatr (Phila) 2011; 50:757.</a></li><li><a class="nounderline abstract_t">Boos MD, Castelo-Soccio L. Experience with topical timolol maleate for the treatment of ulcerated infantile hemangiomas (IH). J Am Acad Dermatol 2016; 74:567.</a></li><li><a class="nounderline abstract_t">Mannschreck DB, Huang AH, Lie E, et al. Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. Pediatr Dermatol 2019; 36:283.</a></li><li><a class="nounderline abstract_t">Ovadia SA, Landy DC, Cohen ER, et al. Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis. Ann Plast Surg 2015; 74:256.</a></li><li><a class="nounderline abstract_t">Püttgen K, Lucky A, Adams D, et al. Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Gan LQ, Wang H, Ni SL, Tan CH. A prospective study of topical carteolol therapy in Chinese infants with superficial infantile hemangioma. Pediatr Dermatol 2018; 35:121.</a></li><li><a class="nounderline abstract_t">Muñoz-Garza FZ, Ríos M, Roé-Crespo E, et al. Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial. JAMA Dermatol 2021; 157:583.</a></li><li><a class="nounderline abstract_t">Garzon MC, Lucky AW, Hawrot A, Frieden IJ. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy. J Am Acad Dermatol 2005; 52:281.</a></li><li><a class="nounderline abstract_t">Chen MT, Yeong EK, Horng SY. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases. J Pediatr Surg 2000; 35:420.</a></li><li><a class="nounderline abstract_t">Couto JA, Greene AK. Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants. J Plast Reconstr Aesthet Surg 2014; 67:1469.</a></li><li><a class="nounderline abstract_t">Ceisler EJ, Santos L, Blei F. Periocular hemangiomas: what every physician should know. Pediatr Dermatol 2004; 21:1.</a></li><li><a class="nounderline abstract_t">Mills CM, Marks R. Side effects of topical glucocorticoids. Curr Probl Dermatol 1993; 21:122.</a></li><li><a class="nounderline abstract_t">Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998; 38:318.</a></li><li><a class="nounderline abstract_t">Olsen EA, Cornell RC. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. J Am Acad Dermatol 1986; 15:246.</a></li><li><a class="nounderline abstract_t">Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics 2012; 130:e314.</a></li><li><a class="nounderline abstract_t">Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics 2013; 131:128.</a></li><li class="breakAll">Hemangeol (propranolol hydrochloride oral solution). US FDA approved product information; Parsippany, NJ: Pierre Fabre Pharmaceuticals, Inc; March 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205410s000lbl.pdf (Accessed on March 30, 2016).</li><li><a class="nounderline abstract_t">Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358:2649.</a></li><li><a class="nounderline abstract_t">Ozeki M, Nozawa A, Hori T, et al. Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor. Pediatr Int 2016; 58:1130.</a></li><li><a class="nounderline abstract_t">Kum JJ, Khan ZA. Mechanisms of propranolol action in infantile hemangioma. Dermatoendocrinol 2014; 6:e979699.</a></li><li><a class="nounderline abstract_t">Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128:e259.</a></li><li><a class="nounderline abstract_t">Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009; 124:e423.</a></li><li><a class="nounderline abstract_t">Buckmiller L, Dyamenahalli U, Richter GT. Propranolol for airway hemangiomas: case report of novel treatment. Laryngoscope 2009; 119:2051.</a></li><li><a class="nounderline abstract_t">Denoyelle F, Leboulanger N, Enjolras O, et al. Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. Int J Pediatr Otorhinolaryngol 2009; 73:1168.</a></li><li><a class="nounderline abstract_t">Theletsane T, Redfern A, Raynham O, et al. Life-threatening infantile haemangioma: a dramatic response to propranolol. J Eur Acad Dermatol Venereol 2009; 23:1465.</a></li><li><a class="nounderline abstract_t">Truong MT, Chang KW, Berk DR, et al. Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr 2010; 156:335.</a></li><li><a class="nounderline abstract_t">Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med 2015; 372:735.</a></li><li><a class="nounderline abstract_t">Léauté-Labrèze C, Frieden I, Delarue A. Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate. Pediatr Dermatol 2023; 40:261.</a></li><li><a class="nounderline abstract_t">Chinnadurai S, Fonnesbeck C, Snyder KM, et al. Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis. Pediatrics 2016; 137:e20153896.</a></li><li><a class="nounderline abstract_t">Novoa M, Baselga E, Beltran S, et al. Interventions for infantile haemangiomas of the skin. Cochrane Database Syst Rev 2018; 4:CD006545.</a></li><li><a class="nounderline abstract_t">Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol 2011; 28:94.</a></li><li><a class="nounderline abstract_t">Vivas-Colmenares GV, Bernabeu-Wittel J, Alonso-Arroyo V, et al. Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase. Pediatr Dermatol 2015; 32:348.</a></li><li><a class="nounderline abstract_t">Garzon MC, Epstein LG, Heyer GL, et al. PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. J Pediatr 2016; 178:24.</a></li><li><a class="nounderline abstract_t">Gatts JE, Rush MC, Check JF, et al. Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. Pediatr Dermatol 2022; 39:389.</a></li><li><a class="nounderline abstract_t">Gomes R, Salazar L, Fraga C, et al. Management of infantile hemangiomas-experience of a tertiary hospital. Eur J Pediatr 2023; 182:1611.</a></li><li><a class="nounderline abstract_t">Kumar MG, Coughlin C, Bayliss SJ. Outpatient use of oral propranolol and topical timolol for infantile hemangiomas: survey results and comparison with propranolol consensus statement guidelines. Pediatr Dermatol 2015; 32:171.</a></li><li><a class="nounderline abstract_t">Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr 2015; 174:855.</a></li><li><a class="nounderline abstract_t">Solman L, Glover M, Beattie PE, et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. Br J Dermatol 2018; 179:582.</a></li><li><a class="nounderline abstract_t">Smithson SL, Rademaker M, Adams S, et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Australas J Dermatol 2017; 58:155.</a></li><li><a class="nounderline abstract_t">Püttgen KB, Hansen LM, Lauren C, et al. Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. J Am Acad Dermatol 2021; 85:345.</a></li><li><a class="nounderline abstract_t">Martin K, Blei F, Chamlin SL, et al. Propranolol treatment of infantile hemangiomas: anticipatory guidance for parents and caretakers. Pediatr Dermatol 2013; 30:155.</a></li><li><a class="nounderline abstract_t">Baselga E, Dembowska-Baginska B, Przewratil P, et al. Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">Caussé S, Aubert H, Saint-Jean M, et al. Propranolol-resistant infantile haemangiomas. Br J Dermatol 2013; 169:125.</a></li><li><a class="nounderline abstract_t">Shah SD, Baselga E, McCuaig C, et al. Rebound Growth of Infantile Hemangiomas After Propranolol Therapy. Pediatrics 2016; 137.</a></li><li><a class="nounderline abstract_t">Wedgeworth E, Glover M, Irvine AD, et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. Br J Dermatol 2016; 174:594.</a></li><li><a class="nounderline abstract_t">Ahogo CK, Ezzedine K, Prey S, et al. Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. Br J Dermatol 2013; 169:1252.</a></li><li><a class="nounderline abstract_t">Knöpfel N, Oesch V, Theiler M, et al. Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Prey S, Voisard JJ, Delarue A, et al. Safety of Propranolol Therapy for Severe Infantile Hemangioma. JAMA 2016; 315:413.</a></li><li><a class="nounderline abstract_t">Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol 2009; 26:610.</a></li><li><a class="nounderline abstract_t">de Graaf M, Breur JM, Raphaël MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol 2011; 65:320.</a></li><li><a class="nounderline abstract_t">Holland KE, Frieden IJ, Frommelt PC, et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010; 146:775.</a></li><li><a class="nounderline abstract_t">Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol 2011; 28:169.</a></li><li><a class="nounderline abstract_t">Droitcourt C, Kerbrat S, Rault C, et al. Safety of Oral Propranolol for Infantile Hemangioma. Pediatrics 2018; 141.</a></li><li><a class="nounderline abstract_t">Theiler M, Knöpfel N, von der Heydt S, et al. Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study. Eur J Pediatr 2021; 180:2655.</a></li><li><a class="nounderline abstract_t">Thai T, Wang CY, Chang CY, Brown JD. Central Nervous System Effects of Oral Propranolol for Infantile Hemangioma: A Systematic Review and Meta-Analysis. J Clin Med 2019; 8.</a></li><li><a class="nounderline abstract_t">González-Llorente N, Del Olmo-Benito I, Muñoz-Ollero N, et al. Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma. Pediatr Dermatol 2017; 34:554.</a></li><li><a class="nounderline abstract_t">Frieden IJ, Püttgen KB, Drolet BA, et al. Management of infantile hemangiomas during the COVID pandemic. Pediatr Dermatol 2020; 37:412.</a></li><li><a class="nounderline abstract_t">Marey HM, Elmazar HF, Mandour SS, Khairy HA. Combined Oral and Topical Beta Blockers for the Treatment of Early Proliferative Superficial Periocular Infantile Capillary Hemangioma. J Pediatr Ophthalmol Strabismus 2018; 55:37.</a></li><li><a class="nounderline abstract_t">Pope E, Chakkittakandiyil A, Lara-Corrales I, et al. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Br J Dermatol 2013; 168:222.</a></li><li><a class="nounderline abstract_t">Ábarzúa-Araya A, Navarrete-Dechent CP, Heusser F, et al. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. J Am Acad Dermatol 2014; 70:1045.</a></li><li><a class="nounderline abstract_t">Tasani M, Glover M, Martinez AE, Shaw L. Atenolol treatment for infantile haemangioma. Br J Dermatol 2017; 176:1400.</a></li><li><a class="nounderline abstract_t">Ji Y, Wang Q, Chen S, et al. Oral atenolol therapy for proliferating infantile hemangioma: A prospective study. Medicine (Baltimore) 2016; 95:e3908.</a></li><li><a class="nounderline abstract_t">Pope E, Lara-Corrales I, Sibbald C, et al. Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial. JAMA Pediatr 2022; 176:34.</a></li><li><a class="nounderline abstract_t">Ji Y, Chen S, Yang K, et al. Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 2021; 147:599.</a></li><li><a class="nounderline abstract_t">Aly MM, Hamza AF, Abdel Kader HM, et al. Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. Eur J Pediatr 2015; 174:1503.</a></li><li><a class="nounderline abstract_t">Dinehart SM, Kincannon J, Geronemus R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001; 27:475.</a></li><li><a class="nounderline abstract_t">Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg 2000; 37:517.</a></li><li><a class="nounderline abstract_t">Kim KH, Choi TH, Choi Y, et al. Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. JAMA Dermatol 2017; 153:529.</a></li><li><a class="nounderline abstract_t">Malik MA, Menon P, Rao KL, Samujh R. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. J Pediatr Surg 2013; 48:2453.</a></li><li><a class="nounderline abstract_t">Bauman NM, McCarter RJ, Guzzetta PC, et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2014; 140:323.</a></li><li><a class="nounderline abstract_t">Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104:1616.</a></li><li><a class="nounderline abstract_t">Lomenick JP, Backeljauw PF, Lucky AW. Growth, bone mineral accretion, and adrenal function in glucocorticoid-treated infants with hemangiomas-- a retrospective study. Pediatr Dermatol 2006; 23:169.</a></li><li><a class="nounderline abstract_t">George ME, Sharma V, Jacobson J, et al. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 2004; 140:963.</a></li><li><a class="nounderline abstract_t">Kelly ME, Juern AM, Grossman WJ, et al. Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol 2010; 146:767.</a></li><li><a class="nounderline abstract_t">Aviles R, Boyce TG, Thompson DM. Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas. Mayo Clin Proc 2004; 79:243.</a></li><li><a class="nounderline abstract_t">Maronn ML, Corden T, Drolet BA. Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma. Arch Dermatol 2007; 143:1224.</a></li><li><a class="nounderline abstract_t">Stier MF, Glick SA, Hirsch RJ. Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas. J Am Acad Dermatol 2008; 58:261.</a></li><li><a class="nounderline abstract_t">Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10:311.</a></li><li><a class="nounderline abstract_t">McHeik JN, Renauld V, Duport G, et al. Surgical treatment of haemangioma in infants. Br J Plast Surg 2005; 58:1067.</a></li><li><a class="nounderline abstract_t">Samuelov L, Kinori M, Rychlik K, et al. Risk factors for ocular complications in periocular infantile hemangiomas. Pediatr Dermatol 2018; 35:458.</a></li><li><a class="nounderline abstract_t">Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128:255.</a></li><li><a class="nounderline abstract_t">Ni N, Langer P, Wagner R, Guo S. Topical timolol for periocular hemangioma: report of further study. Arch Ophthalmol 2011; 129:377.</a></li><li><a class="nounderline abstract_t">Slaughter K, Sullivan T, Boulton J, et al. Early surgical intervention as definitive treatment for ocular adnexal capillary haemangioma. Clin Exp Ophthalmol 2003; 31:418.</a></li><li><a class="nounderline abstract_t">Schneider D, Lee MS, Harrison AR, Sidman J. Excision of periorbital hemangiomas to correct visual abnormalities. Arch Facial Plast Surg 2011; 13:195.</a></li><li><a class="nounderline abstract_t">Frank RC, Cowan BJ, Harrop AR, et al. Visual development in infants: visual complications of periocular haemangiomas. J Plast Reconstr Aesthet Surg 2010; 63:1.</a></li><li><a class="nounderline abstract_t">Claude O, Picard A, O'Sullivan N, et al. Use of ultrasonic dissection in the early surgical management of periorbital haemangiomas. J Plast Reconstr Aesthet Surg 2008; 61:1479.</a></li><li><a class="nounderline abstract_t">Taban M, Goldberg RA. Propranolol for orbital hemangioma. Ophthalmology 2010; 117:195.</a></li><li><a class="nounderline abstract_t">Fay A, Nguyen J, Jakobiec FA, et al. Propranolol for isolated orbital infantile hemangioma. Arch Ophthalmol 2010; 128:256.</a></li><li><a class="nounderline abstract_t">Al Dhaybi R, Superstein R, Milet A, et al. Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. Ophthalmology 2011; 118:1184.</a></li><li><a class="nounderline abstract_t">Janmohamed SR, Madern GC, Nieuwenhuis K, et al. Evaluation of intra-lesional corticosteroids in the treatment of peri-ocular haemangioma of infancy: still an alternative besides propranolol. Pediatr Surg Int 2012; 28:393.</a></li><li><a class="nounderline abstract_t">Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 1986; 17:229.</a></li><li><a class="nounderline abstract_t">Weiss AH. Adrenal suppression after corticosteroid injection of periocular hemangiomas. Am J Ophthalmol 1989; 107:518.</a></li><li><a class="nounderline abstract_t">Glatt HJ, Putterman AM, Van Aalst JJ, Levine MR. Adrenal suppression and growth retardation after injection of periocular capillary hemangioma with corticosteroids. Ophthalmic Surg 1991; 22:95.</a></li><li><a class="nounderline abstract_t">Sutula FC, Glover AT. Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma. Ophthalmic Surg 1987; 18:103.</a></li><li><a class="nounderline abstract_t">Goyal R, Watts P, Lane CM, et al. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. Ophthalmology 2004; 111:389.</a></li><li><a class="nounderline abstract_t">Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001; 44:962.</a></li><li><a class="nounderline abstract_t">Morelli JG, Tan OT, Yohn JJ, Weston WL. Treatment of ulcerated hemangiomas infancy. Arch Pediatr Adolesc Med 1994; 148:1104.</a></li><li><a class="nounderline abstract_t">Thomas J, Kumar P, Kumar DD. Ulcerated infantile haemangioma of buttock successfully treated with topical timolol. J Cutan Aesthet Surg 2013; 6:168.</a></li><li><a class="nounderline abstract_t">Cante V, Pham-Ledard A, Imbert E, et al. First report of topical timolol treatment in primarily ulcerated perineal haemangioma. Arch Dis Child Fetal Neonatal Ed 2012; 97:F155.</a></li><li><a class="nounderline abstract_t">Beal BT, Chu MB, Siegfried EC. Ulcerated infantile hemangioma: novel treatment with topical brimonidine-timolol. Pediatr Dermatol 2014; 31:754.</a></li><li><a class="nounderline abstract_t">Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011; 64:827.</a></li><li><a class="nounderline abstract_t">Hermans DJ, van Beynum IM, Schultze Kool LJ, et al. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol 2011; 64:833.</a></li><li><a class="nounderline abstract_t">Kim LH, Hogeling M, Wargon O, et al. Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg 2011; 46:759.</a></li><li><a class="nounderline abstract_t">Hong E, Fischer G. Propranolol for recalcitrant ulcerated hemangioma of infancy. Pediatr Dermatol 2012; 29:64.</a></li><li><a class="nounderline abstract_t">Tiwari P, Pandey V, Gangopadhyay AN, et al. Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Oral Maxillofac Surg 2016; 20:73.</a></li><li><a class="nounderline abstract_t">Fernández Faith E, Shah S, Witman PM, et al. Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma. JAMA Dermatol 2021; 157:566.</a></li><li><a class="nounderline abstract_t">Peridis S, Pilgrim G, Athanasopoulos I, Parpounas K. A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. Int J Pediatr Otorhinolaryngol 2011; 75:455.</a></li><li><a class="nounderline abstract_t">Yang W, Wolter NE, Cushing SL, et al. Propranolol versus nadolol for treatment of pediatric subglottic hemangioma. Int J Pediatr Otorhinolaryngol 2021; 144:110688.</a></li><li><a class="nounderline abstract_t">Schwartz T, Faria J, Pawar S, et al. Efficacy and rebound rates in propranolol-treated subglottic hemangioma: A literature review. Laryngoscope 2017; 127:2665.</a></li><li><a class="nounderline abstract_t">Rahbar R, Nicollas R, Roger G, et al. The biology and management of subglottic hemangioma: past, present, future. Laryngoscope 2004; 114:1880.</a></li><li><a class="nounderline abstract_t">Elluru RG, Friess MR, Richter GT, et al. Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas. Otolaryngol Head Neck Surg 2015; 153:452.</a></li><li><a class="nounderline abstract_t">Tal R, Dotan M, Lorber A. Approach to haemangiomatosis causing congestive heart failure. Acta Paediatr 2016; 105:600.</a></li><li><a class="nounderline abstract_t">Ishikawa T, Seki K, Uchiyama H. Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis. Pediatr Dermatol 2022; 39:613.</a></li><li><a class="nounderline abstract_t">Mhanna A, Franklin WH, Mancini AJ. Hepatic infantile hemangiomas treated with oral propranolol--a case series. Pediatr Dermatol 2011; 28:39.</a></li><li><a class="nounderline abstract_t">Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010; 157:340.</a></li><li><a class="nounderline abstract_t">Metry DW, Garzon MC, Drolet BA, et al. PHACE syndrome: current knowledge, future directions. Pediatr Dermatol 2009; 26:381.</a></li><li><a class="nounderline abstract_t">Siegel DH, Tefft KA, Kelly T, et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke 2012; 43:1672.</a></li></ol></div><div id="topicVersionRevision">Topic 5792 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416931" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and Management of Infantile Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416928" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis and Management of Infantile Hemangioma: Executive Summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28089471" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Infantile haemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9344205" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9420551" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Which hemangiomas to treat--and how?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676554" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Growth characteristics of infantile hemangiomas: implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30584062" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical Practice Guideline for the Management of Infantile Hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22575857" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Infantile hemangioma: clinical assessment of the involuting phase and implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21460670" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Untreated hemangiomas: growth pattern and residual lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27540637" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk Factors for Degree and Type of Sequelae After Involution of Untreated Hemangiomas of Infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9481012" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Growing up with a facial hemangioma: parent and child coping and adaptation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890993" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Benign cutaneous vascular tumors of infancy: when to worry, what to do.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10403856" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hemangiomas in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23701395" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Haemangioma: clinical course, complications and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32161112" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Infantile Hemangioma Referral Score: A Validated Tool for Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21525081" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : β-blockers for infantile hemangiomas: a single-institution experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26892656" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Experience with topical timolol maleate for the treatment of ulcerated infantile hemangiomas (IH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30968438" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25590249" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Local administration ofβ-blockers for infantile hemangiomas: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27527799" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Topical Timolol Maleate Treatment of Infantile Hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29243341" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A prospective study of topical carteolol therapy in Chinese infants with superficial infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33825828" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy and Safety of Topical Timolol for the Treatment of Infantile Hemangioma in the Early Proliferative Stage: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692474" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ultrapotent topical corticosteroid treatment of hemangiomas of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10726680" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of 155 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25104131" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Management of problematic infantile hemangioma using intralesional triamcinolone: efficacy and safety in 100 infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14871317" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Periocular hemangiomas: what every physician should know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8299365" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Side effects of topical glucocorticoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486706" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3528243" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Topical clobetasol-17-propionate: review of its clinical efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22826568" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Early growth of infantile hemangiomas: what parents' photographs tell us.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23266923" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23266923" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18550886" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Propranolol for severe hemangiomas of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26991797" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26413184" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mechanisms of propranolol action in infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21788220" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A randomized controlled trial of propranolol for infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706583" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Propranolol for severe infantile hemangiomas: follow-up report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19650125" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Propranolol for airway hemangiomas: case report of novel treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19481268" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19453811" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Life-threatening infantile haemangioma: a dramatic response to propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20105647" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25693013" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A randomized, controlled trial of oral propranolol in infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36511888" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26772662" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29667726" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Interventions for infantile haemangiomas of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21362031" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25721095" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effectiveness of propranolol in the treatment of infantile hemangioma beyond the proliferation phase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27659028" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35243678" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36705724" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Management of infantile hemangiomas-experience of a tertiary hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25556828" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Outpatient use of oral propranolol and topical timolol for infantile hemangiomas: survey results and comparison with propranolol consensus statement guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26021855" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of infantile haemangiomas: recommendations of a European expert group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29774538" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28251611" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Consensus statement for the treatment of infantile haemangiomas with propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32289387" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23316721" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Propranolol treatment of infantile hemangiomas: anticipatory guidance for parents and caretakers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30082451" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23659587" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Propranolol-resistant infantile haemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26952504" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Rebound Growth of Infantile Hemangiomas After Propranolol Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26473312" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23662995" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32051218" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26813215" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety of Propranolol Therapy for Severe Infantile Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19840322" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Propranolol treatment for hemangioma of infancy: risks and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601311" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644039" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20738795" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29844139" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Safety of Oral Propranolol for Infantile Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34143243" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30813242" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Central Nervous System Effects of Oral Propranolol for Infantile Hemangioma: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28804922" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298480" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Management of infantile hemangiomas during the COVID pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28991344" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Combined Oral and Topical Beta Blockers for the Treatment of Early Proliferative Superficial Periocular Infantile Capillary Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22762503" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24656727" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28112790" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Atenolol treatment for infantile haemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27310994" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Oral atenolol therapy for proliferating infantile hemangioma: A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34747977" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33856430" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25982338" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11359498" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hemangiomas: evaluation and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955029" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Vascular anomalies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28423174" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24314186" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24526257" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10541160" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Complications of systemic corticosteroid therapy for problematic hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650230" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Growth, bone mineral accretion, and adrenal function in glucocorticoid-treated infants with hemangiomas-- a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15313812" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20479291" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14959920" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Pneumocystis carinii pneumonia in a 3-month-old infant receiving high-dose corticosteroid therapy for airway hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17875903" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pneumocystis carinii pneumonia in infant treated with oral steroids for hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068263" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Laser treatment of pediatric vascular lesions: Port wine stains and hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8302734" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The current management of vascular birthmarks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16039624" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Surgical treatment of haemangioma in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29766557" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Risk factors for ocular complications in periocular infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142555" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21403002" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Topical timolol for periocular hemangioma: report of further study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14516430" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Early surgical intervention as definitive treatment for ocular adnexal capillary haemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576666" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Excision of periorbital hemangiomas to correct visual abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19097831" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Visual development in infants: visual complications of periocular haemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037085" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Use of ultrasonic dissection in the early surgical management of periorbital haemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20114117" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Propranolol for orbital hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142556" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Propranolol for isolated orbital infantile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292326" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22200732" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Evaluation of intra-lesional corticosteroids in the treatment of peri-ocular haemangioma of infancy: still an alternative besides propranolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3714192" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2540659" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Adrenal suppression after corticosteroid injection of periocular hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2038483" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Adrenal suppression and growth retardation after injection of periocular capillary hemangioma with corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3574861" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Eyelid necrosis following intralesional corticosteroid injection for capillary hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15019396" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11369908" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Ulcerated hemangiomas: clinical characteristics and response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7921107" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Treatment of ulcerated hemangiomas infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24163539" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Ulcerated infantile haemangioma of buttock successfully treated with topical timolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22190187" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : First report of topical timolol treatment in primarily ulcerated perineal haemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25424217" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Ulcerated infantile hemangioma: novel treatment with topical brimonidine-timolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353332" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Propranolol for treatment of ulcerated infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353329" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21496551" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21854419" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Propranolol for recalcitrant ulcerated hemangioma of infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26481918" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33787840" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21333364" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33773428" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Propranolol versus nadolol for treatment of pediatric subglottic hemangioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28833230" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Efficacy and rebound rates in propranolol-treated subglottic hemangioma: A literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15510009" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The biology and management of subglottic hemangioma: past, present, future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124263" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26859502" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Approach to haemangiomatosis causing congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35575222" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21261702" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Hepatic infantile hemangiomas treated with oral propranolol--a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488455" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19689512" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : PHACE syndrome: current knowledge, future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22442177" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
